Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered

Journal of Clinical Oncology

Volumn 17, Issue 12, 1999, Pages 3767-3775

  Byrd, John C ^a   Dodge, Richard K ^a   Carroll, Andrew ^a   Baer, Maria R ^a   Edwards, Colin ^a   Stamberg, Judith ^a   Qumsiyeh, Mazin ^a   Moore, Joseph O ^a   Mayer, Robert J ^a   Davey, Frederick ^a   Schiffer, Charles A ^a   Bloomfield, Clara D ^a  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; MITOXANTRONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW TOXICITY; CANCER REGRESSION; CANCER SURVIVAL; CARDIOTOXICITY; CHROMOSOME TRANSLOCATION 8; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; FEVER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; LUNG TOXICITY; MALE; NAUSEA; NEUROTOXICITY; PRIORITY JOURNAL; SKIN TOXICITY; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; VOMITING;

EID: 0032793987     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1999.17.12.3767     Document Type: Article

References (38)

1. Dastugue N, Payen C, Lafage-Pochitaloff M, et al: Prognostic significance of karyotype in de novo adult acute myelogenous leukemia. Leukemia 9:1491-1498, 1995
2. Stasi R, Del Poeta G, Masi M, et al: Incidence of chromosome abnormalities and clinical significance of karyotype in de novo acute myeloid leukemia. Cancer Genet Cytogenet 167:28-34, 1993
3. Schiffer CA, Lee EJ, Tomiyasu T, et al: Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. Blood 73:263-270, 1989
4. Mrözek K, Heinonen K, de la Chapelle A, et al: Clinical significance of cytogenetics in acute myeloid leukemia. Semin Oncol 24:17-31, 1997
5. Berger R, Bernhein A, Ochoa-Noguera ME, et al: Prognostic significance of chromosomal abnormalities in acute nonlymphocytic leukemia: A study of 343 patients. Cancer Genet Cytogen 28:293-299, 1987
6. Keating MJ, Smith TL, Kantarjian H, et al: Cytogenetic pattern of acute myelogenous leukemia: A major reproducible determinate of outcome. Leukemia 2:403-412, 1988
7. Bloomfield CD, Shuma C, Regal L, et al: Long-term survival of patients with acute myeloid leukemia. Cancer 80:2191-2198, 1997
8. Skipper HE, Schaebel FM Jr, Wilcox WS: Experimental evaluation of potential anticancer agents: XIII. On the criteria and kinetics associated with "curability" of experimental leukemia. Cancer Chemother Rep 35:1-11, 1964
9. Wolff SN, Herzig RH, Fay JW, et al: High-dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: Long-term follow-up and results. J Clin Oncol 7:1260-1267, 1989
10. Mayer RJ, Davis RB, Schiffer CA, et al: Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 331:896-903, 1994
11. Bishop JF, Matthews JP, Young GA, et al: A randomized study of high-dose cytarabine in induction of acute leukemia. Blood 87:1710-1717, 1996
12. Weick JK, Kopecky KJ, Appelbaum FR, et al: A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group Study. Blood 88:2841-2851, 1996
13. Bloomfield CD, Lawerence D, Arthur DC, et al: Curative impact of intensification with high-dose cytarabine in acute myeloid leukemia varies by cytogenetic group. Blood 84:111a, 1994 (abstr)
14. Bloomfield CD, Lawrence DL, Byrd JC, et al: Frequency of prolonged remission duration following high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 58:4173-4179, 1998
15. Döhner H, Fischer K, del Valle F, et al: Stratification of postremission therapy in adult acute myeloid leukemia according to the karyotype: First results of the AML HD93 multicenter treatment trial. Blood 90: 584a, 1997 (abstr)
16. Garson OM, Matthews JP, Bishop JF: Prognostic significance of cytogenetic abnormalities in adult acute myeloid leukemia patients treated with high dose cytarabine. Blood 86: 600a, 1995 (abstr)
17. Moore JO, Powell B, Velez-Garcia E, et al: A comparison of sequential non-cross resistant therapy or Ara-C consolidation following complete remission in adult patients < 60 years with acute myeloid leukemia: CALGB 9222. Proc Am Soc Clin Oncol 16:14a, 1997 (abstr)
18. Cassileth P, Harrington D, Paietta E, et al: Comparison of autologous bone marrow transplant with high-dose cytarabine in acute myeloid leukemia in first remission: An ECOG intergroup study. Proc Am Soc Clin Oncol 16:89, 1997 (abstr)
19. Bennett JM, Catovsky D, Daniel MT, et al: Proposed revised criteria for the classification of acute myeloid leukemia: A report of the French-American-British Cooperative Group. Ann Intern Med 103:626-629, 1985
20. Moore JO, Dodge RK, Amrein PC, et al: Granulocyte-colony stimulating factor accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and Leukemia Group B Study 9022. Blood 89:780-788, 1997
21. Mayer RJ, Schiffer CA, Petterson BA, et al: Intensive postremission therapy in adults with acute nonlymphocytic leukemia using various dose schedules of Ara-C: A progress report from the CALGB. Semin Oncol, 14:25-31, 1987 (suppl 1)
22. Mitelman F (ed): ISCN (1995): An International System for Human Cytogenetic Nomenclature. Basel, Switzerland, S. Karger, 1995
23. Byrd JC, Weiss RB, Arthur DC, et al: Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): Results from the Cancer and Leukemia Group B 8461. J Clin Oncol 15:466-475, 1997
24. O'Brien S, Kantarjian HM, Keating MJ, et al: Association of granulocytosis with poor prognosis in patients with acute myelogenous leukemia and translocation of chromosome 8 and 21. J Clin Oncol 7:1081-1086, 1989
25. Baer MR, Stewart CC, Lawrence D, et al: Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22). Blood 90:1643-1650, 1997
26. Cheson BD, Cassileth PA, Head DR, et al: Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myelogenous leukemia. J Clin Oncol 8:813-819, 1990
27. Armitage P: Statistical Methods in Medical Research. London, England, Blackwell Scientific, 1971
28. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
29. Peto R, Pike MC, Armitage P, et al: Design and analysis of randomized clinical trials requiring prolonged observation of each patient: II. Analysis and examples. Br J Cancer 35:1-39, 1977
30. Zittoun RA, Mandelli F, Willemze R, et al: Autologous or allogeneic bone marrow transplant compared with intensive chemotherapy in acute myeloid leukemia. N Engl J Med 332:217-223, 1995
31. Harousseau JL, Cahn JY, Pignon B, et al: Comparison of autologous bone marrow transplantation versus intensive chemotherapy as post-remission therapy in adult acute myeloblastic leukemia. Blood 90:2978-2986, 1997
32. Schoch C, Haase D, Haferlach T, et al: Fifty-one patients with acute myeloid leukemia and translocation t(8;21)(q22;q22): An additional deletion in 9q is an adverse prognostic factor. Leukemia 10:1288-1295, 1996
33. Tricot G, Orshoven BV, Daele CV, et al: 8;21 translocation in acute myeloid leukaemia. Scand J Haematol 26:168-176, 1981
34. Tosi P, Visani G, Ottaviani E, et al: Inv(16) acute myeloid leukemia cells show inv(16) chromosomal abnormality have an increased sensitivity to cytosine arabinoside in vitro. Eur J Haematol 60:161-165, 1998
35. Pearson L, Leith CP, Duncan MH, et al: Multidrug resistance-1 (MDR1) expression and functional dye/drug efflux is highly correlated with the t(8;21) chromosomal translocation in pediatric acute myeloid leukemia. Leukemia 10:1274-1282, 1996
36. Burnett AK, Wheatley K, Langabeer H, et al: Outcome of acute myeloid leukemia affecting core binding factor subunits: The UK MRC experience. Blood 90: 390a, 1997 (abstr)
37. Burnett AK, Goldstone AH, Stevens RMF, et al: Randomized comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: Results of MRC AML 10 trial. Lancet 351:700-708, 1998
38. Slovak ML, Kopecky KJ, Cassileth PA, et al: Karyotype analysis predicts outcome of pre- and post-remission therapy in adult acute myeloid leukemia: A SWOG/ECOG intergroup trial. Blood 92: 678a, 1998 (abstr)